Endologix Company Profile (NASDAQ:ELGX)

About Endologix

Endologix logoEndologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company's products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX), the VELA Proximal Endograft (VELA) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). Its EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). It offers accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Instruments & Supplies
  • Sub-Industry: Health Care Supplies
  • Exchange: NASDAQ
  • Symbol: ELGX
  • CUSIP: 29266S10
Key Metrics:
  • Previous Close: $6.49
  • 50 Day Moving Average: $6.54
  • 200 Day Moving Average: $9.37
  • 52-Week Range: $4.78 - $14.49
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.33
  • P/E Growth: -0.24
  • Market Cap: $539.97M
  • Outstanding Shares: 82,691,000
  • Beta: 0.87
Profitability:
  • Net Margins: -78.53%
  • Return on Equity: -39.12%
  • Return on Assets: -13.36%
Debt:
  • Debt-to-Equity Ratio: 1.31%
  • Current Ratio: 2.47%
  • Quick Ratio: 1.75%
Additional Links:
Companies Related to Endologix:

Analyst Ratings

Consensus Ratings for Endologix (NASDAQ:ELGX) (?)
Ratings Breakdown: 7 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.30)
Consensus Price Target: $10.38 (58.96% upside)

Analysts' Ratings History for Endologix (NASDAQ:ELGX)
Show:
DateFirmActionRatingPrice TargetDetails
2/23/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$10.00View Rating Details
1/12/2017BMO Capital MarketsDowngradeOutperform -> Market Perform$14.00 -> $9.50View Rating Details
1/6/2017BTIG ResearchReiterated RatingBuy$11.00 -> $9.00View Rating Details
1/6/2017RBC Capital MarketsReiterated RatingHold$8.00View Rating Details
12/28/2016Canaccord GenuityReiterated RatingHold$7.50 -> $6.30View Rating Details
12/7/2016Leerink SwannReiterated RatingMarket Perform$11.00 -> $8.00View Rating Details
12/4/2016J P Morgan Chase & CoDowngradeOverweight -> Neutral$14.00 -> $10.00View Rating Details
11/16/2016GuggenheimDowngradeBuy -> NeutralView Rating Details
8/3/2016Piper Jaffray CompaniesReiterated RatingOverweight$15.00View Rating Details
8/3/2016Royal Bank Of CanadaDowngradeOutperform -> Sector Perform$17.00 -> $12.00View Rating Details
2/22/2016Credit Suisse GroupLower Price TargetOutperform$16.00 -> $10.00View Rating Details
2/2/2016Stifel NicolausLower Price TargetBuy$17.00 -> $15.00View Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for Endologix (NASDAQ:ELGX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/22/2017        
2/22/2017Q4 2016($0.19)($0.22)$48.69 million$47.46 millionViewN/AView Earnings Details
11/1/2016Q316($0.15)($0.18)$51.83 million$52.12 millionViewN/AView Earnings Details
5/9/2016Q1($0.24)($0.25)$38.78 million$42.40 millionViewN/AView Earnings Details
2/22/2016Q4($0.16)($0.17)$39.97 million$39.20 millionViewListenView Earnings Details
10/26/2015Q315($0.14)($0.13)$38.12 million$38.20 millionViewListenView Earnings Details
8/3/2015Q215($0.13)($0.18)$39.47 million$39.50 millionViewN/AView Earnings Details
4/29/2015Q115($0.13)($0.14)$37.94 million$36.70 millionViewN/AView Earnings Details
2/25/2015Q414($0.10)($0.11)$38.10 million$38.80 millionViewN/AView Earnings Details
10/30/2014Q314($0.13)($0.13)$37.00 million$37.20 millionViewListenView Earnings Details
7/30/2014Q214($0.08)($0.06)$36.50 million$38.30 millionViewListenView Earnings Details
4/30/2014Q114($0.08)($0.08)$32.24 million$33.30 millionViewListenView Earnings Details
2/27/2014Q413($0.05)($0.05)$35.80 million$35.25 millionViewListenView Earnings Details
10/30/2013Q313($0.05)$0.01$32.47 million$33.30 millionViewN/AView Earnings Details
7/30/2013Q2 2013($0.06)($0.03)$33.94 million$34.00 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.06)($0.15)$29.26 million$29.80 millionViewN/AView Earnings Details
2/27/2013Q4 2012($0.03)($0.09)$29.03 million$29.22 millionViewN/AView Earnings Details
10/25/2012($0.04)($0.03)ViewN/AView Earnings Details
7/26/2012($0.04)($0.09)ViewN/AView Earnings Details
4/26/2012($0.06)($0.07)ViewN/AView Earnings Details
2/22/2012($0.05)($0.06)ViewN/AView Earnings Details
10/27/2011($0.05)($0.09)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Endologix (NASDAQ:ELGX)
Current Year EPS Consensus Estimate: $-0.75 EPS
Next Year EPS Consensus Estimate: $-0.70 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.24)($0.24)($0.24)
Q2 20161($0.22)($0.22)($0.22)
Q3 20162($0.17)($0.17)($0.17)
Q4 20162($0.16)($0.15)($0.16)
Q1 20172($0.23)($0.22)($0.23)
Q2 20172($0.18)($0.14)($0.16)
Q3 20172($0.16)($0.11)($0.14)
Q4 20172($0.13)($0.10)($0.12)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Endologix (NASDAQ:ELGX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Endologix (NASDAQ:ELGX)
Insider Ownership Percentage: 3.90%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/14/2016John D McdermottCEOBuy10,000$6.67$66,700.00View SEC Filing  
12/14/2016Thomas F Zenty IIIDirectorBuy3,000$6.51$19,530.00View SEC Filing  
12/13/2016Vaseem MahboobCFOBuy20,000$6.25$125,000.00View SEC Filing  
11/18/2016Guido J NeelsDirectorBuy13,000$7.69$99,970.00View SEC Filing  
8/19/2016Jose A LimaVPSell4,710$11.68$55,012.80View SEC Filing  
8/5/2016Michael V ChobotovInsiderSell14,000$12.40$173,600.00View SEC Filing  
6/3/2016Gregory D WallerDirectorSell7,800$12.86$100,308.00View SEC Filing  
6/1/2016Amanda L DepalmaVPSell689$12.55$8,646.95View SEC Filing  
6/1/2016John D McdermottCEOSell6,116$12.55$76,755.80View SEC Filing  
6/1/2016Joseph A DejohnInsiderSell957$12.55$12,010.35View SEC Filing  
6/1/2016Robert D MitchellPresidentSell2,294$12.55$28,789.70View SEC Filing  
5/26/2016James Edward MachekVPSell6,500$12.76$82,940.00View SEC Filing  
1/26/2016Charles Steele LoveVPSell4,280$7.72$33,041.60View SEC Filing  
11/3/2015Guido J NeelsDirectorBuy11,000$9.32$102,520.00View SEC Filing  
11/3/2015Todd AbrahamVPBuy2,500$8.85$22,125.00View SEC Filing  
11/2/2015John D McdermottCEOBuy20,000$8.90$178,000.00View SEC Filing  
9/3/2015Jose A LimaVPSell1,923$12.60$24,229.80View SEC Filing  
5/26/2015Thomas WilderDirectorSell3,790$16.08$60,943.20View SEC Filing  
5/20/2015Jose A LimaVPSell1,872$16.75$31,356.00View SEC Filing  
4/6/2015Robert D MitchellPresidentSell45,000$17.33$779,850.00View SEC Filing  
12/12/2014Charles Steele LoveVPSell10,000$13.95$139,500.00View SEC Filing  
11/18/2014Charles Steele LoveVPBuy2,000$11.70$23,400.00View SEC Filing  
11/4/2014Guido J NeelsDirectorBuy10,000$11.21$112,100.00View SEC Filing  
11/4/2014John D McdermottCEOBuy25,000$11.25$281,250.00View SEC Filing  
8/4/2014Thomas WilderDirectorSell3,500$13.68$47,880.00View SEC Filing  
6/12/2014Robert D MitchellPresidentSell18,271$14.23$259,996.33View SEC Filing  
6/10/2014Robert D MitchellPresidentSell8,516$14.20$120,927.20View SEC Filing  
8/14/2013Stefan SchreckVPSell25,000$16.18$404,500.00View SEC Filing  
8/13/2013Stefan SchreckVPSell29,000$15.88$460,520.00View SEC Filing  
8/5/2013Gary SorsherVPSell12,483$15.98$199,478.34View SEC Filing  
8/5/2013John McdermottCEOSell165,000$16.00$2,640,000.00View SEC Filing  
8/2/2013Todd AbrahamVPSell9,994$15.90$158,904.60View SEC Filing  
8/1/2013John D McdermottCEOSell15,000$15.83$237,450.00View SEC Filing  
6/3/2013Thomas WilderDirectorSell22,500$13.25$298,125.00View SEC Filing  
5/28/2013Leonard M GreensteinVPSell1,253$14.01$17,554.53View SEC Filing  
12/28/2012Robert John KristCFOSell37,530$14.06$527,671.80View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Endologix (NASDAQ:ELGX)
DateHeadline
News IconNASDAQ:ELGX Shareholder Notice: Deadline on March 6, 2017in Lawsuit against Endologix, Inc. (NASDAQ:ELGX)
www.groundreport.com - February 22 at 10:13 PM
capitalcube.com logoEndologix, Inc. breached its 50 day moving average in a Bearish Manner : ELGX-US : February 22, 2017 (NASDAQ:ELGX)
us.rd.yahoo.com - February 22 at 10:13 PM
us.rd.yahoo.com logoSHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Endologix Inc. (ELGX) and Lead Plaintiff Deadline: March 6, 2017 (NASDAQ:ELGX)
us.rd.yahoo.com - February 22 at 10:13 PM
us.rd.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Endologix, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 6, 2017 (NASDAQ:ELGX)
us.rd.yahoo.com - February 22 at 10:13 PM
us.rd.yahoo.com logoEndologix Reports Results for the Fourth Quarter and Full Year 2016 (NASDAQ:ELGX)
us.rd.yahoo.com - February 22 at 10:13 PM
us.rd.yahoo.com logo4:11 pm Endologix misses by $0.12, misses on revs; guides FY17 revs in-line (NASDAQ:ELGX)
us.rd.yahoo.com - February 22 at 10:13 PM
biz.yahoo.com logoENDOLOGIX INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition (NASDAQ:ELGX)
us.rd.yahoo.com - February 22 at 10:13 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Endologix, Inc. of Commencement of a Class ... - Yahoo Finance (NASDAQ:ELGX)
finance.yahoo.com - February 22 at 5:13 PM
finance.yahoo.com logoEndologix reports 4Q loss - Yahoo Finance (NASDAQ:ELGX)
finance.yahoo.com - February 22 at 5:13 PM
News IconTechnical Study: Following Indicators for Endologix Inc (ELGX) - Rives Journal (NASDAQ:ELGX)
rivesjournal.com - February 22 at 5:13 PM
sg.finance.yahoo.com logoEndologix reports 4Q loss (NASDAQ:ELGX)
sg.finance.yahoo.com - February 22 at 5:13 PM
News IconAnalysts Peer Into Their Crystal Balls For Endologix, Inc. (NASDAQ:ELGX): Where Is It headed? - Winfield Review (NASDAQ:ELGX)
winfieldreview.com - February 22 at 7:43 AM
News IconSell-side Taking Aim at Shares of Endologix, Inc. (NASDAQ:ELGX) - Aiken Advocate (NASDAQ:ELGX)
aikenadvocate.com - February 22 at 7:43 AM
News IconEndologix, Inc. (ELGX): Essential Chart Information - NY Stock News (NASDAQ:ELGX)
nystocknews.com - February 22 at 7:43 AM
News IconGlobal Coronary Stents (Bare Metal, Drug-Eluting, Bioresorable) Market 2016-2021 - Bioresorbable Stents as the Future (NASDAQ:ELGX)
www.econotimes.com - February 20 at 11:23 AM
finance.yahoo.com logoIMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Endologix, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:ELGX)
finance.yahoo.com - February 20 at 11:23 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Endologix, Inc. of Class Action Lawsuit and Upcoming Deadline - ELGX (NASDAQ:ELGX)
finance.yahoo.com - February 18 at 10:49 AM
4-traders.com logoLundin Law PC Announces Securities Class Action Lawsuit Against Endologix, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:ELGX)
www.4-traders.com - February 17 at 5:41 PM
us.rd.yahoo.com logoEGLX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Endologix, Inc. and a Lead Plaintiff Deadline of March 6, 2017 (NASDAQ:ELGX)
us.rd.yahoo.com - February 17 at 5:41 PM
us.rd.yahoo.com logoENDOLOGIX LOSS NOTICE: Rosen Law Firm Reminds Endologix Inc. Investors of Important Deadline in Class Action Filed by Firm - ELGX (NASDAQ:ELGX)
us.rd.yahoo.com - February 16 at 9:39 PM
us.rd.yahoo.com logoENDOLOGIX LOSS NOTICE: Rosen Law Firm Reminds Endologix Inc. Investors of Important Deadline in Class Action Filed by Firm - ELGX (NASDAQ:ELGX)
us.rd.yahoo.com - February 16 at 9:39 PM
News IconImpact of Brokerage Rating on Endologix, Inc.(ELGX) - Morning Outlook (NASDAQ:ELGX)
www.morningoutlook.com - February 15 at 8:49 PM
globenewswire.com logoENDOLOGIX LOSS NOTICE: Rosen Law Firm Reminds Endologix Inc. Investors of Important Deadline in Class Action ... - GlobeNewswire (press release) (NASDAQ:ELGX)
globenewswire.com - February 15 at 8:49 PM
News IconEndologix Completes Patient Enrollment in the Ovation LUCY Study (NASDAQ:ELGX)
www.pressreleasepoint.com - February 15 at 3:55 AM
streetinsider.com logoEndologix (ELGX) Says It Completed Patient Enrollment in Ovation LUCY Study (NASDAQ:ELGX)
www.streetinsider.com - February 15 at 3:55 AM
News IconMarket Scope: Viewing Shares of Endologix, Inc. (NASDAQ:ELGX) - Rives Journal (NASDAQ:ELGX)
rivesjournal.com - February 14 at 10:52 PM
News IconMarket Update: Watching Shares of Endologix Inc. (ELGX) - BVN (NASDAQ:ELGX)
bvnewsjournal.com - February 14 at 10:52 PM
News IconStock Spotlight: Zooming in on Shares of Endologix, Inc. (NASDAQ:ELGX) - Piedmont Register (NASDAQ:ELGX)
piedmontregister.com - February 14 at 5:52 PM
News IconSell-side is Weighing in on Endologix, Inc. (NASDAQ:ELGX) Earnings - Aiken Advocate (NASDAQ:ELGX)
aikenadvocate.com - February 14 at 5:52 PM
streetinsider.com logoEndologix (ELGX) Says It Completed Patient Enrollment in Ovation LUCY Study - StreetInsider.com (NASDAQ:ELGX)
www.streetinsider.com - February 14 at 5:52 PM
finance.yahoo.com logoEndologix Completes Patient Enrollment in the Ovation® LUCY Study (NASDAQ:ELGX)
finance.yahoo.com - February 14 at 5:52 PM
finance.yahoo.com logoEGLX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Endologix, Inc. and a Lead Plaintiff Deadline of March 6, 2017 (NASDAQ:ELGX)
finance.yahoo.com - February 13 at 5:42 PM
biz.yahoo.com logoENDOLOGIX INC /DE/ Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits (NASDAQ:ELGX)
us.rd.yahoo.com - February 8 at 5:27 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Endologix, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 6, 2017 (NASDAQ:ELGX)
finance.yahoo.com - February 8 at 5:27 PM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Endologix Inc., and Encourages Investors with Losses to Contact the Firm (NASDAQ:ELGX)
finance.yahoo.com - February 8 at 5:27 PM
us.rd.yahoo.com logoEndologix to Report Fourth Quarter and Full Year 2016 Financial Results on February 22, 2017 (NASDAQ:ELGX)
us.rd.yahoo.com - February 7 at 6:06 PM
us.rd.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Endologix Inc. (ELGX) and Lead Plaintiff Deadline: March 6, 2017 (NASDAQ:ELGX)
us.rd.yahoo.com - February 7 at 6:06 PM
fool.com logoWhy Endologix, Inc. Stock Gained 20% in January (NASDAQ:ELGX)
www.fool.com - February 7 at 3:59 PM
finance.yahoo.com logo9:04 am Endologix to separate the positions of Chairman and CEO; Dan Lemaitre, Lead Independent Director, has been appointed Chairman, and John McDermott, will continue to serve as CEO and Director (NASDAQ:ELGX)
finance.yahoo.com - February 6 at 4:59 PM
finance.yahoo.com logoEndologix Announces Appointment of Dan Lemaitre as Chairman of the Board (NASDAQ:ELGX)
finance.yahoo.com - February 6 at 9:17 AM
businesswire.com logoEGLX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Endologix, Inc. and a Lead Plaintiff Deadline of March 6, 2017 (NASDAQ:ELGX)
www.businesswire.com - February 3 at 10:20 PM
us.rd.yahoo.com logoSHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Endologix Inc. (ELGX) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit (NASDAQ:ELGX)
us.rd.yahoo.com - February 3 at 10:20 PM
News IconFinancial Update of Endologix, Inc. (NASDAQ:ELGX) - The Newburgh Press (NASDAQ:ELGX)
newburghpress.com - February 3 at 5:20 PM
finance.yahoo.com logoEndologix to Present at Leerink Partners 6th Annual Global Healthcare Conference (NASDAQ:ELGX)
finance.yahoo.com - February 3 at 5:20 PM
finance.yahoo.com logoIMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Endologix Inc., and Encourages Investors with Losses to Contact the Firm (NASDAQ:ELGX)
finance.yahoo.com - February 2 at 10:27 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Endologix, Inc. To Contact The Firm Before Lead Plaintiff Deadline (NASDAQ:ELGX)
finance.yahoo.com - February 2 at 5:25 PM
finance.yahoo.com logoINVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Endologix Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:ELGX)
finance.yahoo.com - February 1 at 5:30 PM
einnews.com logoELGX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Endologix ... - U.S. Politics Today (NASDAQ:ELGX)
www.einnews.com - January 30 at 3:18 PM
globenewswire.com logoELGX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Endologix ... - GlobeNewswire (press release) (NASDAQ:ELGX)
www.globenewswire.com - January 30 at 12:25 PM
4-traders.com logoKhang & Khang LLP Announces Securities Class Action Lawsuit against Endologix Inc., and Encourages Investors with Losses to Contact the Firm (NASDAQ:ELGX)
www.4-traders.com - January 28 at 5:07 PM

Social

What is Endologix's stock symbol?

Endologix trades on the NASDAQ under the ticker symbol "ELGX."

Where is Endologix's stock going? Where will Endologix's stock price be in 2017?

10 analysts have issued 1 year target prices for Endologix's shares. Their forecasts range from $6.30 to $16.00. On average, they expect Endologix's stock price to reach $10.38 in the next twelve months.

When will Endologix announce their earnings?

Endologix is scheduled to release their next quarterly earnings announcement on Wednesday, February, 22nd 2017.

What are analysts saying about Endologix stock?

Here are some recent quotes from research analysts about Endologix stock:

  • According to Zacks Investment Research, "Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis. " (1/23/2017)

  • Canaccord Genuity analysts commented, "We note the company’s next-gen AFX2 system incorporates design improvements as well as an updated IFU to decrease the occurrence of Type III endoleaks (zero Type III endoleaks have been reported with AFX2 platform in Europe)." (12/13/2016)

Who owns Endologix stock?

Endologix's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Arrowpoint Asset Management LLC (7.85%), Columbia Wanger Asset Management LLC (7.64%), Brown Capital Management LLC (7.39%), FMR LLC (2.96%), Janus Capital Management LLC (2.13%) and State Street Corp (1.89%). Company insiders that own Endologix stock include Amanda L Depalma, Charles Steele Love, Gregory D Waller, Guido J Neels, James Edward Machek, John D Mcdermott, Jose A Lima, Joseph A Dejohn, Michael V Chobotov, Robert D Mitchell, Thomas F Zenty III, Thomas Wilder, Todd Abraham and Vaseem Mahboob.

Who sold Endologix stock? Who is selling Endologix stock?

Endologix's stock was sold by a variety of institutional investors in the last quarter, including Janus Capital Management LLC, GRT Capital Partners L.L.C., NN Investment Partners Holdings N.V. and Metropolitan Life Insurance Co. NY. Company insiders that have sold Endologix stock in the last year include Amanda L Depalma, Gregory D Waller, James Edward Machek, John D Mcdermott, Jose A Lima, Joseph A Dejohn, Michael V Chobotov and Robert D Mitchell.

Who bought Endologix stock? Who is buying Endologix stock?

Endologix's stock was purchased by a variety of institutional investors in the last quarter, including Columbia Wanger Asset Management LLC, Brown Capital Management LLC, Arrowpoint Asset Management LLC, Broadfin Capital LLC, FMR LLC, Marshall Wace LLP, State Street Corp and Two Sigma Investments LP. Company insiders that have bought Endologix stock in the last two years include Guido J Neels, John D Mcdermott, Thomas F Zenty III, Todd Abraham and Vaseem Mahboob.

How do I buy Endologix stock?

Shares of Endologix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Endologix stock cost?

One share of Endologix stock can currently be purchased for approximately $6.53.

Endologix (NASDAQ:ELGX) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Endologix (NASDAQ:ELGX)

Earnings History Chart

Earnings by Quarter for Endologix (NASDAQ:ELGX)

Dividend History Chart

Dividend Payments by Quarter for Endologix (NASDAQ:ELGX)

Last Updated on 2/23/2017 by MarketBeat.com Staff